IDSA, SHEA Announce New Clostridioides Difficile Clinical Guidelines
The organizations set out 3 recommendations for initial and recurrent C diff treatment.
The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) announced today it had added 3 new evidence-based guidelines for the treatment of Clostridioides difficile infection (CDI) in adults.
The guidelines, developed by a multidisciplinary panel with representatives from IDSA and SHEA, include 3 recommendations on suggested treatments for patients with initial and recurring CDI episodes, based on new data for fidaxomicin and for bezlotoxumab, a monoclonal antibody targeting toxin B produced by C. difficile.
According to the panel, the recommendations are the result of systematic review of available evidence and an assessment of the benefits and harms of alternative care options. The panel adhered to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence and strength of recommendations. The guidelines are intended to aid clinicians in determining which treatments are best for individual patient scenarios.
The IDSA's journal Clinical Infectious Diseases has published the guidelines.